Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 68 Ovarian Neoplasms 44 Breast Neoplasms 26 Lung Neoplasms 23 Fallopian Tube Neoplasms 22 Small Cell Lung Carcinoma 14 Neoplasms 14 Carcinoma, Ovarian Epithelial 14 Triple Negative Breast Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 12 Glioblastoma 12 Recurrence 11 Head and Neck Neoplasms 10 Endometrial Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 9 Colorectal Neoplasms 9 Uterine Cervical Neoplasms 8 Stomach Neoplasms 8 Hodgkin Disease 8 Brain Neoplasms 8 Esophageal Neoplasms 7 Central Nervous System Neoplasms 7 Neoplasm Metastasis 6 Lymphoma 6 Glioma 6 Astrocytoma 6 Adenocarcinoma of Lung 6 Prostatic Neoplasms 5 Lymphoma, Mantle-Cell 5 Gliosarcoma 5

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡